Legal firm looks into claims on behalf of investors of Fulgent Genetics, Inc.

Fulgent Genetics recently made public, in their annual report submitted to the U.S. Securities and Exchange Commission on February 28, 2025, that they were served with a civil investigative demand from the Department of Health and Human Services Office of Inspector General concerning potential violations related to their billing practices. This regulatory scrutiny is centered on possible improper billing for genetic testing services provided by the company.

The civil investigative demand received by Fulgent Genetics requests information and documents related to their billing procedures, specifically focusing on the coding and billing for genetic tests that were conducted. The company is committed to cooperating fully with the Department of Health and Human Services Office of Inspector General to provide all necessary information and documentation in response to this demand.

Fulgent Genetics has stated that they have implemented measures to enhance their compliance efforts and ensure adherence to all regulatory requirements. The company emphasized their dedication to maintaining the highest ethical standards and compliance with all applicable laws and regulations governing their operations.

In response to the disclosure of the civil investigative demand, Fulgent Genetics’ stock prices experienced a decline. Investors may be monitoring the situation closely to assess any potential impact on the company’s financial performance and reputation. It is essential for Fulgent Genetics to address these regulatory concerns effectively and transparently to mitigate any adverse effects on their business operations and stakeholder confidence.

The investigation into Fulgent Genetics’ billing practices highlights the importance of compliance and transparency in the healthcare industry. Regulatory oversight plays a crucial role in ensuring that companies adhere to ethical standards and regulations to protect the interests of consumers and the integrity of the healthcare system.

As Fulgent Genetics navigates through this regulatory inquiry, it is crucial for the company to maintain open communication with regulators and stakeholders while demonstrating a commitment to rectifying any potential issues identified. By addressing the concerns raised by the Department of Health and Human Services Office of Inspector General promptly and effectively, Fulgent Genetics can work towards resolving this matter and upholding their reputation as a responsible and compliant healthcare provider.

Overall, the civil investigative demand received by Fulgent Genetics underscores the importance of regulatory compliance and ethical billing practices in the healthcare industry. The company’s response to this inquiry will be closely monitored by stakeholders and investors as they strive to address these concerns and uphold the highest standards of integrity and transparency in their operations.